Vazalore is a drug owned by Plx Pharma Inc. It is protected by 7 US drug patents filed from 2014 to 2023. Out of these, 4 drug patents are active and 3 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Sep 29, 2032. Details of Vazalore's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US10786444 | PH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same |
Sep, 2032
(7 years from now) | Active |
| US10646431 | PH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same |
Sep, 2032
(7 years from now) | Active |
| US9216150 | pH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same |
Sep, 2032
(7 years from now) | Active |
| US9226892 | pH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same |
Sep, 2032
(7 years from now) | Active |
| US9101637 | Methods of treating inflammation with compositions comprising lecithin oils and NSAIDS for protecting the gastrointestinal tract and providing enhanced therapeutic activity |
Mar, 2022
(3 years ago) |
Expired
|
| US8865187 | Compositions comprising lecithin oils and NSAIDs for protecting the gastrointestinal tract and providing enhanced therapeutic activity |
Mar, 2022
(3 years ago) |
Expired
|
| US9351984 | Compositions comprising lecithin oils and NSAIDs for protecting the gastrointestinal tract and providing enhanced therapeutic activity |
Dec, 2021
(3 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Vazalore's patents.
Latest Legal Activities on Vazalore's Patents
Given below is the list of recent legal activities going on the following patents of Vazalore.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Yr, Small Entity | 14 Mar, 2024 | US10786444 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 25 Oct, 2023 | US10646431 |
| Expire Patent Critical | 18 Sep, 2023 | US9101637 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 02 Aug, 2023 | US9226892 |
| 7.5 yr surcharge - late pmt w/in 6 mo, Small Entity | 02 Aug, 2023 | US9226892 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 07 Jun, 2023 | US9216150 |
| Maintenance Fee Reminder Mailed Critical | 03 Apr, 2023 | US9101637 |
| Expire Patent Critical | 28 Nov, 2022 | US8865187 |
| Maintenance Fee Reminder Mailed Critical | 13 Jun, 2022 | US8865187 |
| Recordation of Patent Grant Mailed Critical | 29 Sep, 2020 | US10786444 |
While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Vazalore and ongoing litigations to help you estimate the early arrival of Vazalore generic.
Vazalore's Litigations
Vazalore been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jan 02, 2014, against patent number US8865187. The petitioner , challenged the validity of this patent, with Lenard M. Lichtenberger as the respondent. Click below to track the latest information on how companies are challenging Vazalore's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US8865187 | January, 2014 |
Decision
(17 Jun, 2014) | Lenard M. Lichtenberger | |
US patents provide insights into the exclusivity only within the United States, but Vazalore is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Vazalore's family patents as well as insights into ongoing legal events on those patents.
Vazalore's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Vazalore's generic launch date based on the expiry of its last outstanding patent is estimated to be Sep 29, 2032 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Vazalore Generics:
There are no approved generic versions for Vazalore as of now.
Alternative Brands for Vazalore
Vazalore which is used for targeting release to the small intestine, reducing fever, and relieving minor aches and pains., has several other brand drugs in the same treatment category and using the same active ingredient (Aspirin). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Bionpharma |
| |||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Aspirin. Given below is the list of those drugs and companies owning them.
| Drug Owner | Drug Name | |
|---|---|---|
| Boehringer Ingelheim |
| |
| Bristol Myers Squibb |
| |
| Genus Lifesciences |
| |
| Haleon Us Holdings |
|
About Vazalore
Vazalore is a drug owned by Plx Pharma Inc. It is used for targeting release to the small intestine, reducing fever, and relieving minor aches and pains. Vazalore uses Aspirin as an active ingredient. Vazalore was launched by Plx Pharma in 2021.
Approval Date:
Vazalore was approved by FDA for market use on 26 February, 2021.
Active Ingredient:
Vazalore uses Aspirin as the active ingredient. Check out other Drugs and Companies using Aspirin ingredient
Treatment:
Vazalore is used for targeting release to the small intestine, reducing fever, and relieving minor aches and pains.
Dosage:
Vazalore is available in capsule form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 325MG | CAPSULE | Over the counter | ORAL |
| 81MG | CAPSULE | Over the counter | ORAL |